Collaborative Arrangements and Licensing Agreements (Tables)

9 Months Ended

Sep. 30, 2023

AstraZeneca [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the three and nine months ended September 30, 2023 and 2022, we earned the following revenue from our relationship with AstraZeneca (in thousands, except percentages):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2023			2022			2023			2022
Revenue from our relationship with AstraZeneca	$	15,959		$	18,107		$	99,885		$	55,718
Percentage of total revenue		11	%		11	%		22	%		13	%

Biogen [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the three and nine months ended September 30, 2023 and 2022, we earned the following revenue from our relationship with Biogen (in thousands, except percentages):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2023			2022			2023			2022
Revenue from our relationship with Biogen	$	94,695		$	88,959		$	262,599		$	259,713
Percentage of total revenue		66	%		56	%		57	%		60	%

GSK [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the three and nine months ended September 30, 2023 and 2022, we earned the following revenue from our relationship with GSK (in thousands, except percentages):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2023			2022			2023			2022
Revenue from our relationship with GSK	$	—		$	—		$	15,000		$	—
Percentage of total revenue		0	%		0	%		3	%		0	%

Novartis [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the three and nine months ended September 30, 2023 and 2022, we earned the following revenue from our relationship with Novartis (in thousands, except percentages):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2023			2022			2023			2022
Revenue from our relationship with Novartis	$	1,908		$	—		$	2,023		$	—
Percentage of total revenue		1	%		0	%		0	%		0	%

Roche [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the three and nine months ended September 30, 2023 and 2022, we earned the following revenue from our relationship with Roche (in thousands, except percentage amounts):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2023			2022			2023			2022
R&D revenue	$	8,858		$	41,504		$	16,979		$	65,360
Percentage of total revenue		6	%		26	%		4	%		15	%

Sobi [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the three and nine months ended September 30, 2023 and 2022, we earned the following revenue from our distribution agreement with Sobi for TEGSEDI in North America (in thousands, except percentage amounts).

	Three Months Ended September 30,						Nine Months Ended September 30,
	2023			2022			2023			2022
TEGSEDI revenue from our distribution agreement with Sobi in North America	$	794		$	1,008		$	2,189		$	3,443
Percentage of total revenue		1	%		1	%		2	%		1	%